Alternate TextTo enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.

Benzamil (hydrochloride)

  Cat. No.:  DC26053   Featured
Chemical Structure
161804-20-2
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
Benzamil hydrochloride is a specific and potent sodium channel (ENaC) blocker.
Cas No.: 161804-20-2
Chemical Name: benzamil hydrochloride
Synonyms: benzamil hydrochloride;3,5-diamino-N-(N'-benzylcarbamimidoyl)-6-chloropyrazine-2-carboxamide,hydrochloride;Benzamil;Benzylamiloride hydrochloride;Benzamil HCl;Benzamil hydrochloride hydrate;N-(Benzylamidino)-3,5-diamino-6-chloropyrazinecarboxamide hydrochloride hydrate;Prestwick_985;Benzamil hydrate hydrochloride;N-(Benzylamidino)-3,5-diamino-6-chloropyrazinecarboxamide hydrate hydrochloride
SMILES: O=C(NC(=N)NCC1C=CC=CC=1)C1C(N)=NC(N)=C(Cl)N=1.[H]Cl
Formula: C13H15Cl2N7O
M.Wt: 356.210499048233
Purity: >98%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Description: Benzamil hydrochloride is a specific blocker of sodium channel (ENaC).
Target: Sodium channel[1]
In Vivo: Intracerebroventricular injection of endothelin-1 (1 nmol) after intracerebroventricular preinjection of the vehicle of Benzamil hydrochloride markedly increases both mean arterial pressure and abdominal sympathetic nervous activity for 10 min. In SHRSP, intracerebroventricular infusion either of 1 or 10 nmol/kg/day Benzamil hydrochloride decreases systolic blood pressure (4th day: F=6.131, 1 nmol/kg/day, P<0.05, 10 nmol/kg/day, P<0.01; 5th day: F=6.842, 1 nmol/kg/day, P<0.05, 10 nmol/kg/day, P<0.01; 6th day: F=5.988, 1 nmol/kg/day, P<0.05, 10 nmol/kg/day, P<0.01; 7th day: F=7.935, 1 nmol/kg/day, P<0.01, 10 nmol/kg/day, P<0.01), urinary excretion of vasopressin (5th day: F=9.385, 1 nmol/kg/day, P<0.05, 10 nmol/kg/day, P<0.05; 6th day: F=8.783, 1 nmol/kg/day, P<0.01, 10 nmol/kg/day, P<0.01; 7th day: F=8.996, 1 nmol/kg/day, P<0.01, 10 nmol/kg/day, P< 0.01), and norepinephrine (3rd day: F=4.341, 1 nmol/kg/day, P<0.05, 10 nmol/kg/day, P<0.01; 4th day: F=9.865, 1 nmol/kg/day, P<0.01, 10 nmol/kg/day, P<0.01; 5th day: F=14.652, 1 nmol/kg/day, P<0.01, 10 nmol/kg/day, P<0.01; 6th day: F=13.376, 1 nmol/kg/day, P<0.01, 10 nmol/kg/day, P<0.01; 7th day: F=8.594, 1 nmol/kg/day, P<0.01, 10 nmol/kg/day, P<0.01) compare with vehicle[1].
In Vitro: The specific ENaC blocker Benzamil hydrochloride adds to the luminal perfusate (10−6 M) significantly decreases baseline [Na+]i by 19.2 mM (n=5) and almost completely inhibits the [NaCl]L-dependent increasing in [Na+]i when coadministers with luminal AngII[2].
Cell Assay: Individual CCD segments are dissected from rabbit and mouse kidney.The measurements of [Na+]i are used as a reflection of Na+ transport across the apical membrane. EnaC-specific activity is assessed by applying 10−6 M of the ENaC blocker Benzamil hydrochloride, a concentration that does not affect Na+:H+ exchange. Experiments are performed in the presence/absence of luminal Benzamil hydrochloride or the Na:H exchanger blocker HOE694 administers with/without the AT1 receptor blocker candesartan. Final DMSO concentrations are below 0.1% [2].
Animal Administration: For the acute intracerebroventricular injection in anesthetized rats. A guide cannula is inserted into the right lateral cerebral ventricle, and Benzamil hydrochloride (0.1 nmol/kg, n=6; 1 nmol/kg, n=6; 10 nmol/kg,n=7) or vehicle (n=6) is injected into the right lateral ventricle through a cannula connected to a microsyringe 15 min before the start of intracerebroventricular infusion of hypertonic NaCl. Each injection consists of a volume of 10 μL deliver manually over a period of 30 s. To investigate the effects of Benzamil hydrochloride on the pressor response induced by intracerebroventricular injection of the pressor agent other than hypertonic NaCl, endothelin-1, which has a potent pressor action in the brain of rats, is intracerebroventricularly injected (1 nmol/10 μL) 15 min after the intracerebroventricular preinjection of Benzamil hydrochloride (10 nmol/kg, n=6) or the vehicle (n=6), and mean arterial pressure, heart rate, and abdominal sympathetic nerve firings are recorded for 20 min. Catheters are implanted into both the femoral artery and vein of 12-wk-old male rats anesthetized with urethan. Both catheters are filled with heparinized saline (50 U/mL). Fifteen minutes before the start of intracerebroventricular infusion of hypertonic NaCl, Benzamil hydrochloride (10 nmol/kg, n=6) or vehicle (10 μL, n=6) is injected into a tube connects to the femoral venous catheter by directly inserting the microsyringe, and 0.1 ml of isotonic saline solution is injected through the catheter to deliver the contents into the venous circulation[1].
References: [1]. Nishimura M, et al. Benzamil blockade of brain Na+ channels averts Na(+)-induced hypertension in rats. Am J Physiol. 1998 Mar;274(3 Pt 2):R635-44. [2]. Peti-Peterdi J, et al. Angiotensin II directly stimulates ENaC activity in the cortical collecting duct via AT(1) receptors. J Am Soc Nephrol. 2002 May;13(5):1131-5.
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
Cat. No. Product name Field of application
DC31074 Isopropyl myristate Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC75868 AZ14133346 AZ14133346 (compound 36) is a potent and selective inhibitor of EGFR Exon20 insertions, with the IC50 of 85 nM. AZ14133346 plays an important role in cancer research.
DC75865 TI17 ​​TI17​​ represents a novel class of targeted anticancer agents that specifically disrupt DNA damage repair mechanisms in malignant cells.
DC75816 Nisoxetine Nisoxetine acts as a highly selective and potent noradrenaline transporter (NET) antagonist, exhibiting a binding affinity (Kd) of 0.76 nM. In addition to its antidepressant properties, nisoxetine functions as a local anesthetic by inhibiting voltage-gated sodium channels. This dual pharmacological activity makes it a compound of interest for both neurological and pain management research.
DC75641 GENZ-644282 TFA salt Genz-644282, also known as SAR402674, is a non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity. Topoisomerase I inhibitor Genz-644282 binds to and inhibits the enzyme topoisomerase I, which may result in the inhibition of repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations.
DC75325 PSMA-617 TFA PSMA-617, also know as vipivotide tetraxetan, is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer. PSMA617 possesses a small peptide, which was designed to target prostate-specific membrane antigen (PSMA). PSMA617 demonstrates high radiolytic stability for at least 72 h. PSMA617 has high inhibition potency (equilibrium dissociation constant Ki=2.34±2.94 nM on LNCaP; Ki=0.37±0.21 nM enzymatically determined). 177 Lu-PSMA-617 offers a potential additional life-prolonging treatment option for men with mCRPC.
DC75202 Fosaprepitant free acid Fosaprepitant, also known as MK0517, is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant, the active moiety, is a substrate, inhibitor, and inducer of CYP3A4
DC74748 O4I4 O4I4 (compound 23) is a OCT4-inducing compound with metabolical stability.
DC74684 ZH8667 ZH8667 is a trace amine-associated receptor 1 (TAAR1)–Gs agonist.
DC74646 EB-PSMA-617 EB-PSMA-617 is an Evans blue-modified prostate-specific membrane antigen (PSMA) 617 ligand for making 177Lu-EB-PSMA, which is potential useful for Metastatic Castration-Resistant Prostate Cancer.
X